Trials / No Longer Available
No Longer AvailableNCT00701168
Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer
A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Leo W. Jenkins Cancer Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- —
Summary
The purpose of this protocol is to provide supervised and limited access to Therasphere® treatment for patients with primary liver cancer and chemotherapy refractory liver metastasis who cannot be treated by surgical removal of the affected part of the liver. Patient response to treatment and any side effects of Therasphere® treatment will be examined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | yttrium Y 90 microspheres (Therasphere®) | This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances. |
Timeline
- First posted
- 2008-06-19
- Last updated
- 2017-08-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00701168. Inclusion in this directory is not an endorsement.